Evaluation of type-specific HPV persistence and high-risk HPV viral load quantitation in HPV positive women under 30 with normal cervical cytology

Journal of Medical Virology

Volumn 83, Issue 4, 2011, Pages 637-643

  Carcopino, Xavier ^a,b,c   Bolger, Noel ^d   Henry, Mireille ^e   Mancini, Julien ^e   Boubli, Léon ^a   Olive, Daniel ^c   Cleary, Sinead ^d   Prendiville, Walter ^d   Tamalet, Catherine ^e  

^a HÔPITAL NORD   (France)

^b University of Marseille   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d Pathology Research Laboratory   (Ireland)

^e TIMONE HOSPITAL   (France)

Author keywords

Cervical cancer; Genotyping; Human papillomavirus; Screening; Viral load

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 58; MAJOR CLINICAL STUDY; MOLECULAR CLONING; PAPILLOMAVIRUS INFECTION; PERSISTENT VIRUS INFECTION; PHYLOGENY; REAL TIME POLYMERASE CHAIN REACTION; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; VIRUS LOAD; VIRUS TYPING; WART VIRUS;

ADOLESCENT; ADULT; CERVIX UTERI; CLUSTER ANALYSIS; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PHYLOGENY; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PREVALENCE; SEQUENCE ANALYSIS, DNA; VIRAL LOAD; YOUNG ADULT;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 79951541743     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22022     Document Type: Article

References (36)

1. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. 2006. Chapter 9: Clinical applications of HPV testing: A summary of meta-analyses. Vaccine 24: S78-S89.
2. Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P, Prendiville W, Paraskevaidis E. 2008. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: Meta-analysis. Br Med J 337: a1284.
3. Bae J, Seo SS, Park YS, Dong SM, Kang S, Myung SK, Park SY. 2009. Natural history of persistent high-risk human papillomavirus infections in Korean women. Gynecol Oncol 115: 75-80.
4. Bosch FX, Munoz N. 2002. The viral etiology of cervical cancer. Virus Res 89: 183-190.
5. Carcopino X, Henry M, Benmoura D, Fallabregues AS, Richet H, Boubli L, Tamalet C. 2006. Determination of HPV type 16 and 18 viral load in cervical smears of women referred to colposcopy. J Med Virol 78: 1131-1140.
6. Cibas ES, Hong X, Crum CP, Feldman S. 2007. Age-specific detection of high risk HPV DNA in cytologically normal, computer-imaged ThinPrep Pap samples. Gynecol Oncol 104: 702-706.
7. Committee on Adolescent Health Care. 2009. ACOG Committee Opinion No. 436: Evaluation and management of abnormal cervical cytology and histology in adolescents. Obstet Gynecol 113: 1422-1425.
8. Cotton SC, Sharp L, Seth R, Masson LF, Little J, Cruickshank ME, Neal K, Waugh N. 2007. Lifestyle and socio-demographic factors associated with high-risk HPV infection in UK women. Br J Cancer 97: 133-139.
9. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, Gie C, Ho L, Jacobs I, Pickles C, Sasieni P. 2003. Management of women who test positive for high-risk types of human papillomavirus: The HART study. Lancet 362: 1871-1876.
10. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T. 2006. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119: 1095-1101.
11. Dalstein V, Riethmuller D, Pretet JL, Le Bail Carval K, Sautiere JL, Carbillet JP, Kantelip B, Schaal JP, Mougin C. 2003. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: A longitudinal French cohort study. Int J Cancer 106: 396-403.
12. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Desy M, Rohan TE. 1999. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 180: 1415-1423.
13. Gravitt PE, Kovacic MB, Herrero R, Schiffman M, Bratti C, Hildesheim A, Morales J, Alfaro M, Sherman ME, Wacholder S, Rodriguez AC, Burk RD. 2007. High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int J Cancer 121: 2787-2793.
14. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. 1998. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338: 423-428.
15. Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ, Verheijen RH, Fransen-Daalmeijer N, Meijer CJ. 2000. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: The age-related patterns for high-risk and low-risk types. Int J Cancer 87: 221-227.
16. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M. 2005. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97: 1072-1079.
17. Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E. 2007. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: A systematic review and meta-analysis of non-randomized studies. Gynecol Oncol 104: 232-246.
18. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. 2006. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: Systematic review and meta-analysis. Lancet 367: 489-498.
19. Lai CH, Chao A, Chang CJ, Chao FY, Huang HJ, Hsueh S, Lin CT, Cheng HH, Huang CC, Yang JE, Wu TI, Chou HH, Chang TC. 2008. Host and viral factors in relation to clearance of human papillomavirus infection: A cohort study in Taiwan. Int J Cancer 123: 1685-1692.
20. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlee F, Franco EL. 2007. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 357: 1579-1588.
21. Moberg M, Gustavsson I, Gyllensten U. 2004. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer 112: 854-859.
22. Moberg M, Gustavsson I, Wilander E, Gyllensten U. 2005. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer 92: 891-894.
23. Munoz N, Hernandez-Suarez G, Mendez F, Molano M, Posso H, Moreno V, Murillo R, Ronderos M, Meijer C, Munoz A. 2009. Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women. Br J Cancer 100: 1184-1190.
24. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJ. 1999. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: A prospective study. Lancet 354: 20-25.
25. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV PATRICIA Study Group, Greenacre M. 2009. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 374(9686): 301-314.
26. Pretet JL, Jacquard AC, Carcopino X, Charlot JF, Bouhour D, Kantelip B, Soubeyrand B, Leocmach Y, Mougin C, Riethmuller D. 2007. Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in France: EDITH study. Int J Cancer 122: 428-432.
27. Ralston Howe E, Li Z, McGlennen RC, Hellerstedt WL, Downs LS, Jr. 2009. Type-specific prevalence and persistence of human papillomavirus in women in the United States who are referred for typing as a component of cervical cancer screening. Am J Obstet Gynecol 200(245): e241-e247.
28. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA. 2009. HPV screening for cervical cancer in rural India. N Engl J Med 360: 1385-1394.
29. Saunier M, Monnier-Benoit S, Mauny F, Dalstein V, Briolat J, Riethmuller D, Kantelip B, Schwarz E, Mougin C, Pretet JL. 2008. Analysis of human papillomavirus type 16 (HPV16) DNA load and physical state for identification of HPV16-infected women with high-grade lesions or cervical carcinoma. J Clin Microbiol 46: 3678-3685.
30. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL. 2001. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 286: 3106-3114.
31. Tamalet C, Richet H, Carcopino X, Henry M, Leretraite L, Heid P, Leandri FX, Sancho-Garnier H, Piana L. 2010. Testing for human papillomavirus and measurement of viral load of HPV 16 and 18 in self-collected vaginal swabs of women who do not undergo cervical cytological screening in southern France. J Med Virol 82: 1431-1437.
32. van Duin M, Snijders PJ, Schrijnemakers HF, Voorhorst FJ, Rozendaal L, Nobbenhuis MA, van den Brule AJ, Verheijen RH, Helmerhorst TJ, Meijer CJ. 2002. Human papillomavirus 16 load in normal and abnormal cervical scrapes: An indicator of CIN II/III and viral clearance. Int J Cancer 98: 590-595.
33. Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Holmes KK, Koutsky LA. 2006. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 354: 2645-2654.
34. Winer RL, Feng Q, Hughes JP, O'Reilly S, Kiviat NB, Koutsky LA. 2008. Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis 197: 279-282.
35. Wise J. 2009. Age for starting cervical cancer screening in England will not be lowered. Br Med J 338: b2583.
36. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP, Young LS. 2001. Natural history of cervical human papillomavirus infection in young women: A longitudinal cohort study. Lancet 357: 1831-1836.